2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Fatty Acid Synthase (FASN)

Fatty Acid Synthase (FASN)

Fatty Acid Synthase (FASN)

Related Products

PDF 0.46 MB

Fatty Acid Synthase (FASN) is a multifunctional homodimeric enzyme protein, and it is the major enzyme required for the anabolic conversion of dietary carbohydrates to fatty acids. Fatty acid synthase catalyzes the conversion of acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids.

Human fatty acid synthase is a large homodimeric multifunctional enzyme that synthesizes palmitic acid. The unique carboxyl terminal thioesterase domain of fatty acid synthase hydrolyzes the growing fatty acid chain and plays a critical role in regulating the chain length of fatty acid released. Also, the up-regulation of human fatty acid synthase in a variety of cancer makes the thioesterase a candidate target for therapeutic treatment.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16207
    FGH10019
    		Inhibitor 99.87%
    FGH10019 is a novel sterol regulatory element-binding protein (SREBP) inhibitor with IC50 of 1 μM.
    FGH10019
  • HY-145809
    FASN-IN-5
    		Inhibitor 99.98%
    FASN-IN-5 (example 11), a FASN inhibitor, can be used for the research of TH17- or CSF1 -mediated disease or disorder such as cancer, immunological disorders, and obesity.
    FASN-IN-5
  • HY-111777
    FASN-IN-1
    		Inhibitor 99.90%
    FASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56.
    FASN-IN-1
  • HY-N2486R
    Desoxyrhaponticin (Standard)
    		Inhibitor
    Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.
    Desoxyrhaponticin (Standard)
  • HY-U00436
    FASN-IN-3
    		Inhibitor 98.06%
    FASN-IN-3 is a fatty acid synthase (FASN) inhibitor extracted from patent US20170119786A1, compound 242A.
    FASN-IN-3
  • HY-P10227
    Xelafaslatide
    		Inhibitor 99.88%
    Xelafaslatide is a Fatty acid synthase (Fas) receptor antagonist.
    Xelafaslatide
  • HY-RS04754
    Fasn Mouse Pre-designed siRNA Set A
    		Inhibitor

    Fasn Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fasn gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Fasn Mouse Pre-designed siRNA Set A
  • HY-E70265
    18:0 Coenzyme A triammonium
    		≥99.0%
    18:0 Coenzyme A (triammonium) is a preferred substrate of stearoyl-CoA desaturases (SCDs).
    18:0 Coenzyme A triammonium
  • HY-N0082
    Praeruptorin B
    		Inhibitor 99.95%
    Praeruptorin B is an inhibitor of sterol regulatory element-binding proteins (SREBPs).
    Praeruptorin B
  • HY-128851A
    Coenzyme A trilithium
    		Chemical 98.00%
    Coenzyme A (CoASH) is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids.
    Coenzyme A trilithium
  • HY-117769
    GSK837149A
    		Inhibitor ≥99.0%
    GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on FASN and selectivity for type I FASN (Ki=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer.
    GSK837149A
  • HY-12648
    FASN-IN-4
    		Inhibitor 99.21%
    FASN-IN-4 is a potent inhibitor of fatty acid synthase (FASN) with an IC50 of 10 nM (WO2012064642A1, compound 29). FASN-IN-4 also inhibits SARS-CoV-2 with an EC50 of 18.6 nM.
    FASN-IN-4
  • HY-N3228
    Myrianthic acid
    		Inhibitor ≥98.0%
    Myrianthic acid, a triterpenoid isolated from the root of Myrianthus arboreus, has anticancer activity.
    Myrianthic acid
  • HY-B0218S
    Orlistat-d3
    		Inhibitor
    Orlistat-d3 is a deuterated labeled Orlistat. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity.?Anti-atherosclerotic?effect.
    Orlistat-d<sub>3</sub>
  • HY-128851R
    Coenzyme A (Standard)
    		Chemical
    Coenzyme A (Standard) is the analytical standard of Coenzyme A. This product is intended for research and analytical applications. Coenzyme A (CoASH) is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids[1].
    Coenzyme A (Standard)
  • HY-110354R
    UCM05 (Standard)
    		Inhibitor
    Lysipressin (Standard) is the analytical standard of Lysipressin. This product is intended for research and analytical applications. Lysipressin (Lysine vasopressin) is antidiuretic hormone that have been found in pigs and some marsupial families. Lysipressin induces contraction of the rabbit urinary bladder smooth muscle, activate adenylate-cyclase.
    UCM05 (Standard)
  • HY-P99133
    Anti-Mouse Fas Ligand Antibody (MFL3)
    		Inhibitor
    Anti-Mouse Fas Ligand Antibody is an anti-mouse Fas Ligand IgG antibody inhibitor derived from host Armenian Hamster.
    Anti-Mouse Fas Ligand Antibody (MFL3)
  • HY-113224R
    Desmosterol (Standard)
    		Inhibitor
    Desmosterol (Standard) is the analytical standard of Desmosterol. This product is intended for research and analytical applications. Desmosterol is a cholesterol-like molecule. In the Bloch pathway of cholesterol biosynthesis, Desmosterol is a direct precursor of cholesterol. As an endogenous metabolite, Desmosterol is used to study cholesterol metabolism [1]. Desmosterol is an LXR activator and SREBP inhibitor, which can suppress macrophage inflammasome activation and prevent vascular inflammation and atherosclerosis. A reduction in Desmosterol promotes the production of mitochondrial reactive oxygen species (ROS) in macrophages and pyrin domain-dependent inflammasome activation of NLRP3. Desmosterol holds potential for research in inflammation, metabolism, and cardiovascular diseases [1][2][3].
    Desmosterol (Standard)
  • HY-170570
    PFM046
    		Inhibitor
    PFM046 is the antagonist for liver X receptor (LXR), that inhibits the activation of LXRα and LXRβ with IC50 of 2.04 μM and 1.58 μM. PFM046 inhibits the expression of SCD1 and FASN, upregulates the expression of ABCA1, and exhibits antitumor efficacy in mouse models.
    PFM046
  • HY-N0686R
    Pseudoprotodioscin (Standard)
    		Inhibitor
    Pseudoprotodioscin (Standard) is the analytical standard of Pseudoprotodioscin. This product is intended for research and analytical applications. Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides.
    Pseudoprotodioscin (Standard)
Cat. No. Product Name / Synonyms Application Reactivity